Sign in Subscribe
Drugs

The Folly of Power-Sharing: Why Merger Negotiations Collapse

Strategic Insights

— 1 min read

The planned merger between Glaxo Wellcome and SmithKline Beecham, two leading pharmaceutical firms, has hit a snag due to an irreconcilable difference between the two CEOs, Sir Richard Sykes and Jan Leschly, who cannot agree on who should lead the new entity. This episode highlights the futility of expecting two strong-willed leaders to share power, despite the supposed trend towards flatter corporate structures and the importance of "team players" in modern business.

Key Takeaways:

  • The merger between Glaxo Wellcome and SmithKline Beecham is in jeopardy due to a disagreement between CEOs Sir Richard Sykes and Jan Leschly over who should lead the new company.
  • The concept of power-sharing between two CEOs is "entirely illusory," as companies require strong leaders to succeed.
  • Lord Weinstock's experience as managing director of GEC demonstrates that job titles may not reflect the actual dynamics within a company.
  • The failure of two CEOs to agree on a leadership structure can lead to clashes of culture and personalities, ultimately resulting in the downfall of the merger.
  • Merger negotiations can be messy, as evidenced by the failed Bid process, which Sir Terence Conran led, resulting in his retirement due to the inability to compromise.
  • The combined research and development departments of Glaxo Wellcome and SmithKline Beecham could produce a formidable £2 billion a year, enabling them to develop new prescriptions and cure the world's ills.
  • Sharing overheads and removing the threat of redundancy for thousands of employees would have produced significant savings, potentially reaching £1 billion a year.

Statistics:

  • The combined market value of Glaxo Wellcome and SmithKline Beecham would be £100 billion.
  • The portfolio of Glaxo Wellcome includes Aids drugs Zovirax, Imigran for migraine, Zantac, and anti-depressants.
  • The SKB cabinet houses anti-depressants, antibiotics, and familiar brand names such as Lucozade, Panadol, and Ribena.
  • The merged company's research and development departments would produce a formidable £2 billion a year.
  • Potential cost savings from sharing overheads were estimated to be up to £1 billion a year.
  • The combined portfolio of Glaxo Wellcome and SmithKline Beecham covers prescription and over-the-counter medicines.

Sources:

  • "The Times, 1998"
  • "The Evening Standard"
  • "Business Week"
  • "Wall Street Journal"

Read more